Abstract
Leptomeningeal Carcinomatosis (LC) refers to diffuse seeding of the leptomeninges by tumor metastases and is a rare presentation of solid tumors, particularly breast cancer, lung cancer and malignant melanoma in adults and hematogenous malignancies and primitive neuroectodermal tumor (PNET) in children. Recently, the incidence of LC has been reported to be increasing due to a longer overall survival obtained in patients treated with novel antineoplastic agents. The usual clinical presentation is a multifocal involvement of the neuraxis, with headache and radicular pain being the most common initial symptoms. The most frequent signs are motor deficits, altered mental status and cranial nerve involvement. The treatment of LC remains controversial and no straightforward guidelines exist in the literature. It has a bad prognosis and inevitably fatal outcome despite aggressive therapy.
Keywords: Leptomeningeal carcinomatosis, systemic therapy, intrathecal therapy, chemotherapy, radioterapy, methotrexate, capecitabine, temozolamide, ccnu, bcnu, thiotepa, ara-c, lung cancer, breast cancer, erlotinib, gefitinib, Ommaya, liposomal cytarabine, mafosfamide, topotecan, bevacizumab, medulloblastoma, DepoCyt, MRI, leukemia, CSF cytology
Central Nervous System Agents in Medicinal Chemistry
Title: Newer Avenues for the Treatment of Leptomeningeal Carcinomatosis
Volume: 11 Issue: 1
Author(s): Fausto Meriggi and Alberto Zaniboni
Affiliation:
Keywords: Leptomeningeal carcinomatosis, systemic therapy, intrathecal therapy, chemotherapy, radioterapy, methotrexate, capecitabine, temozolamide, ccnu, bcnu, thiotepa, ara-c, lung cancer, breast cancer, erlotinib, gefitinib, Ommaya, liposomal cytarabine, mafosfamide, topotecan, bevacizumab, medulloblastoma, DepoCyt, MRI, leukemia, CSF cytology
Abstract: Leptomeningeal Carcinomatosis (LC) refers to diffuse seeding of the leptomeninges by tumor metastases and is a rare presentation of solid tumors, particularly breast cancer, lung cancer and malignant melanoma in adults and hematogenous malignancies and primitive neuroectodermal tumor (PNET) in children. Recently, the incidence of LC has been reported to be increasing due to a longer overall survival obtained in patients treated with novel antineoplastic agents. The usual clinical presentation is a multifocal involvement of the neuraxis, with headache and radicular pain being the most common initial symptoms. The most frequent signs are motor deficits, altered mental status and cranial nerve involvement. The treatment of LC remains controversial and no straightforward guidelines exist in the literature. It has a bad prognosis and inevitably fatal outcome despite aggressive therapy.
Export Options
About this article
Cite this article as:
Meriggi Fausto and Zaniboni Alberto, Newer Avenues for the Treatment of Leptomeningeal Carcinomatosis, Central Nervous System Agents in Medicinal Chemistry 2011; 11 (1) . https://dx.doi.org/10.2174/187152411794961068
DOI https://dx.doi.org/10.2174/187152411794961068 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cyclophosphamide: Time to Say Goodnight and Goodbye?
Current Rheumatology Reviews Deciphering the Antibodyome - Peptide Arrays for Serum Antibody Biomarker Diagnostics
Current Proteomics Nanoparticles: Functionalization and Multifunctional Applications in Biomedical Sciences
Current Medicinal Chemistry DNA Repair in Normal and Cancer Stem Cells, with Special Reference to the Central Nervous System
Current Medicinal Chemistry CypA: A Potential Target of Tumor Radiotherapy and/or Chemotherapy
Current Medicinal Chemistry Neurocysticercosis: The Enigmatic Disease
Central Nervous System Agents in Medicinal Chemistry Mechanisms of Resistance to Chemotherapy in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry Antimetastatic Activities and Mechanisms of Bisdioxopiperazine Compounds
Anti-Cancer Agents in Medicinal Chemistry Dietary Phytochemicals in Chemoprevention of Cancer
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Regulation of EMT by Notch Signaling Pathway in Tumor Progression
Current Cancer Drug Targets Drug Repurposing in Chemical Genomics: Can We Learn from the Past to Improve the Future?
Current Topics in Medicinal Chemistry Recent Advances in Use of Topoisomerase Inhibitors in Combination Cancer Therapy
Current Topics in Medicinal Chemistry Targeted Degradation of Proteins by Small Molecules: A Novel Tool for Functional Proteomics†
Combinatorial Chemistry & High Throughput Screening Repositioning of DHFR Inhibitors
Current Topics in Medicinal Chemistry Destabilizing Aneuploidy by Targeting Cell Cycle and Mitotic Checkpoint Proteins in Cancer Cells
Current Drug Targets The Stable Isotope Use in the Exploration of Bioavailability and Metabolism of Magnesium
Current Nutrition & Food Science Papain Mediated Synthesized Gold Nanoparticles Encore the Potency of Bioconjugated Flutamide
Current Pharmaceutical Biotechnology D-Galactose as a Vector for Prodrug Design
Current Topics in Medicinal Chemistry The Role of Mammalian Target of Rapamycin (mTOR) Inhibitors in the Treatment of Solid Tumors
Current Cancer Therapy Reviews Sulfotransferase 1A1 as a Biomarker for Susceptibility to Carcinogenesis: From Molecular Genetics to the Role of Dietary Flavonoids
Current Drug Metabolism